Seeking Alpha
0
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Gilead Sciences Reports: Let's Analyze It

On Wednesday morning Seeking Alpha's Breaking News reported the following results on Gilead Sciences' (GILD) fourth quarter report.

Gilead Q4 EPS up 364%, Harvoni sales >$2.1B

Feb 3 2015, 16:26 ET | About: Gilead Sciences, Inc. (GILD) | By: Douglas W. House, SA News Editor

  • Gilead Sciences (NASDAQ:) Q4 results ($M): Total Revenues: 7,314 (+134.4%); COGS: 1,063 (+24.0%); R&D Expense: 1,045 (+104.3%); SG&A Expense: 876 (+86.0%); Net Income: 3,462 (+337.5%); EPS: 2.18 (+363.8%).
  • Gross Profit: 6,251 (+176.3%); COGS: 14.5% (-33.3%); Gross Margin: 85.5% (+17.9%); Operating Earnings: 4,330 (+238.3%); Operating Earnings Yield: 59.2% (+44.3%); Net Earnings Yield: 47.3% (+86.6%).
  • Sales by product: Harvoni: 2,107; Sovaldi: 1,732 (+999%); Atripla: 925 (-0.9%); Truvada: 897 (+10.2%); Compera/Eviplera: 348 (+32.9%); Stribild: 385 (+88.9%); Viread: 311 (+16.5%); Letairis: 181 (+30.7%); Ranexa: 144 (+10.9%).
  • 2015 Guidance: Net Product Sales: $26B - 27B; Non-GAAP Gross Margin: 87 - 90%; R&D Expense: $3.0B - 3.3B; SG&A Expense: